Blood
Articles in this Issue
Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma
Abstract Understanding the roles of myeloid cells in the tumor microenvironment (TME) has emerged as a promising strategy to identify novel targets to counteract the immunosuppress...
Targeting FXR in hepatocytes: a promising approach to enhance fibrinolysis and reduce deep vein thrombosis risk
Abstract Obesity is a major health issue and a risk factor for venous thromboembolic disease. Plasminogen activator inhibitor 1 (PAI-1), encoded by the gene SERPINE1, is a negative...
HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology
Abstract JAK2V617F is one of the most common mutations in clonal hematopoiesis of indeterminate potential (CHIP) and a major driver of myeloproliferative neoplasms (MPNs). To deter...
Rewriting the natural history of cTTP
Refitting fitness in CLL
FXR activation aids fibrinolysis: targeting PAI-1 in obesity
Long-term follow-up outcomes in congenital thrombotic thrombocytopenic purpura
Abstract Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultrarare thrombotic microangiopathy mediated through inherited deficiency in a disintegrin and metalloprotease...
Mitochondrial DNA via recipient TLR9 acts as a potent first hit in murine transfusion-related acute lung injury
Abstract Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-related mortality. Though the precise mechanism is not fully understood, a 2-hit model is w...
Guardians of the tumor microenvironment: the neutrophil saga
Decoding RNA modifications to unlock new treatments for AML
Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion
Abstract Two gene therapy products have been approved by the US Food and Drug Administration for sickle cell disease. Nearly all patients in the clinical trials that led to approva...
Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL
Abstract Asparaginase-associated pancreatitis (AAP) is a significant complication in pediatric acute lymphoblastic leukemia (ALL) therapy, often leading to treatment delays or disc...
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL
Abstract Venetoclax-obinutuzumab (Ven-Obi) is a standard first-line therapy for chronic lymphocytic leukemia (CLL). The impact of age, fitness, and dose reductions remains unclear....
Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. <i>Blood.</i> 2023;142(25):2159-2174.
Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN
TRALI: beginnings are always messy
Ikeda H, Hideshima T, Fulciniti M, et al. PI3K/p110δ is a novel therapeutic target in multiple myeloma. <i>Blood</i> 2010;116(9):1460-1468.
Mantle cell lymphoma with <i>KMT2A</i> rearrangement
Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells
Abstract Dysregulated RNA modifications contribute to cancer progression and therapy resistance, yet the underlying mechanism often remains unknown. Here, we perform CRISPR-based s...